Program
Carbidopa
Also written as “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, “Levodopa-carbidopa intestinal gel” and “Carbidopa/levodopa/entacapone”.
Its studies are mostly in Parkinson Disease · Dyskinesias · Attention Deficit Disorder with Hyperactivity · Fibromyalgia · Disruptive, Impulse Control, and Conduct Disorders, led by 7 companies.
Drug pageCarbidopa: every studyMany companies study it; this page follows only the 21 they lead. All 55 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 80 open or running | phase 4since Jun 30, 2005 | Dec 10, 2004 | none ahead |
| AbbVieits history only | 60 open or running | phase 3since Jun 8, 2006 | Jun 8, 2006 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 30 open or running | phase 2since Feb 14, 2011 | Jun 5, 2008 | none ahead |
| Amneal Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 30, 2023 | Nov 30, 2023 | none ahead |
| Osmotica Pharmaceutical USits history only | 10 open or running | phase 2since Nov 12, 2007 | Nov 12, 2007 | none ahead |
| Shanghai WD Pharmaceuticalits history only | 10 open or running | phase 1since Feb 12, 2026 | Feb 12, 2026 | none ahead |
| SynAgileits history only | 10 open or running | phase 2since Feb 22, 2021 | Feb 22, 2021 | none ahead |
Also a collaborator on its studies: TFS Trial Form Support and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 10, 2004First study: phase 3 study in Parkinson DiseaseFirst studyNCT00099268 · 747 enrolled · United States, Austria, Belgium and more
- Jun 30, 2005Phase 4 study in Parkinson DiseaseNCT00219284 · 359 enrolled · United States, Puerto Rico
- Aug 23, 2005Phase 3 study in Parkinson DiseaseNCT00134966 · 493 enrolled · United States, Canada, Czechia and more
- Aug 31, 2005Phase 4 study in Parkinson DiseaseNCT00143026 · 184 enrolled · Australia, Philippines, Taiwan and more
- Oct 24, 2006Phase 4 study in Parkinson DiseaseNCT00391898 · 95 enrolled · Spain
- Jan 11, 2008Phase 4 study in Parkinson DiseaseNCT00601978
- Mar 19, 2008Phase 4 study in Parkinson DiseaseNCT00642356 · 14 enrolled · United States
- Sep 7, 2012Phase 4 study in Disruptive, Impulse Control, and Conduct DisordersNCT01683253 · 150 enrolled · Korea, Republic of
TargetBeta
“DOPA decarboxylase inhibitor”ChEMBL 37, by rule
Other programs on DDC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| benserazide, levodopa drug combinationrule | Bial - Portela C | phase 1 | 3 |
Studies
All 8 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01683253Disruptive, Impulse Control, and Conduct Disorders · Korea, Republic of | 4 | Completed | Dec 2014 | 150 |
| NCT00642356Parkinson Disease · United States | 4 | Terminated | May 2009 | 14 |
| NCT00601978Parkinson Disease | 4 | Withdrawn | Nov 2009 | 0 |
| NCT00391898Parkinson Disease · Spain | 4 | Completed | Jun 2008 | 95 |
| NCT00143026Parkinson Disease · Australia, Philippines, Taiwan and more | 4 | Completed | Jun 2006 | 184 |
| NCT00134966Parkinson Disease · United States, Canada, Czechia and more | 3 | Completed | Sep 2007 | 493 |
| NCT00219284Parkinson Disease · United States, Puerto Rico | 4 | Completed | Jul 2008 | 359 |
| NCT00099268Parkinson Disease · United States, Austria, Belgium and more | 3 | Completed | Nov 2008 | 747 |
How it is read
Names in the registry
- “Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)”, 3 entries
- “Levodopa-carbidopa intestinal gel”, 3 entries
- “Carbidopa/levodopa/entacapone”, 3 entries
- “Levodopa-Carbidopa Intestinal Gel”, 2 entries
- “Carbidopa”, 2 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 16 studies
- Dyskinesias, 2 studies
- Attention Deficit Disorder with Hyperactivity, 1 study
- Fibromyalgia, 1 study
- Disruptive, Impulse Control, and Conduct Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.